Abstract: The invention concerns improvements in needle-free devices for delivery of therapeutic and/or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and/or patient.

Abstract: Described herein is a novel enzymatic pathway and acid tolerant Schizosaccharomyces pombe strain exhibiting the same, for producing 3-hydroxypropionic acid by fermentation wherein the S. pombe strain includes nucleotide sequences that encode, and which are operably linked to promoters to express, non-native enzymes that exhibit an oxaloacetate decarboxylase (ODC) activity that converts oxaloacetate to 3-oxopropionate and a 3-oxopropionate reductase (OPR) activity that converts the 3-opropionate to 3-hydroxypropianate. ODC and OPR enzymes are not known to exist in nature, nor is an enzymatic path for making 3-hydroxypropionic acid but particular enzymes exhibiting the requisite activities are herein identified by sequence.

Abstract: The invention relates to a single-use cassette assembly for use in a reusable solid dose formulation delivery actuator device. Such improvements permit delivery of at least one therapeutic or prophylactic compound, or a solid dose formulation including, for example, a vaccine comprising the same with improved safety and reliability. The invention further concerns an improved needle-free method for delivering at least one therapeutic compound or a formulation comprising the same.

Abstract: The invention concerns improvements in needle-free devices for delivery of therapeutic and/or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and/or patient.

Abstract: Fill-finish assemblies facilitating the manufacture of a drug delivery device are disclosed. The fill-finish assembly may include a container, an insertion mechanism, a fluid pathway connection assembly disposed between the container and the insertion mechanism, and a carrier. The insertion mechanism may include a delivery member and an insertion mechanism housing. The insertion mechanism may be configured to move the delivery member from a retracted position inside the insertion mechanism housing to a deployed position outside the insertion mechanism housing. The fluid pathway connection assembly may be selectively activatable to establish fluid communication between the container and the delivery member. The carrier may have a hollow interior containing at least a portion of each of the container, the insertion mechanism, and the fluid pathway connection assembly.

Abstract: Packages for medical products are disclosed. The packages include a housing and a lid attached to said housing. The lid includes a lifting member that contacts an engagement surface on the medical device whereby opening of said lid allows for removal and presentation of the device for hygienic retrieval by the user.

Abstract: Packages for medical products are disclosed. The packages include a housing and a lid attached to said housing. The lid includes a lifting member that contacts an engagement surface on the medical device whereby opening of said lid allows for removal and presentation of the device for hygienic retrieval by the user.

Abstract: Packages for medical products are disclosed. The packages include a housing (12) and a lid (14) attached to said housing. The lid includes a lifting member (30) that contacts an engagement surface (23) on the medical device whereby opening of said lid allows for removal and presentation of the device for hygienic retrieval by the user.

Abstract: The invention concerns improvements in needle-free devices for delivery of therapeutic and/or prophylactic agents, such as solid dose drugs, including vaccines. The needle-free device disclosed herein comprises novel structural arrangements and modes of actuation and operation, resulting in enhanced functionality and benefits to the user and/or patient.

Abstract: The invention relates to a single-use cassette assembly for use in a reusable solid dose formulation delivery actuator device. Such improvements permit delivery of at least one therapeutic or prophylactic compound, or a solid dose formulation including, for example, a vaccine comprising the same with improved safety and reliability. The invention further concerns an improved needle-free method for delivering at least one therapeutic compound or a formulation comprising the same.

Abstract: Fill-finish assemblies facilitating the manufacture of a drug delivery device are disclosed. The fill-finish assembly may include a container, an insertion mechanism, a fluid pathway connection assembly disposed between the container and the insertion mechanism, and a carrier. The insertion mechanism may include a delivery member and an insertion mechanism housing. The insertion mechanism may be configured to move the delivery member from a retracted position inside the insertion mechanism housing to a deployed position outside the insertion mechanism housing. The fluid pathway connection assembly may be selectively activatable to establish fluid communication between the container and the delivery member. The carrier may have a hollow interior containing at least a portion of each of the container, the insertion mechanism, and the fluid pathway connection assembly.

Abstract: The present description relates to genetic tools and methods to facilitate transformation and genetic engineering of industrially-useful yeast/fungal species, such as Issatchenkia orientalis, for which a robust set of genetic tools such as stably inherited and maintained plasmids and functional control sequences is presently lacking. Thus, the present description relates to autonomously replicating sequences (ARSs), RNA polymerase II/III promoters, RNA polymerase II/III terminators, expression cassettes, and vectors comprising same are described herein, as well as uses and methods relating to same, which are functional in I. orientalis.

Abstract: The present disclosure provides expression vectors containing a nucleic acid encoding an RNA polymerase III promoter, a ribozyme, a CRISPR-Cas9 single guide RNA, and an RNA polymerase III terminator, where the ribozyme is 5? to the CRISPR-Cas9 single guide RNA, as well as ribonucleic acids encoded thereby. Further provided are fungal cells containing an expression vector described herein, as well as methods of fungal genome engineering through use of an expression vector described herein.